Example of Journal of Viral Hepatitis format
Recent searches

Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format Example of Journal of Viral Hepatitis format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Journal of Viral Hepatitis — Template for authors

Publisher: Wiley
Categories Rank Trend in last 3 yrs
Infectious Diseases #60 of 288 down down by 33 ranks
Hepatology #20 of 62 down down by 8 ranks
Virology #23 of 69 down down by 9 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 670 Published Papers | 4111 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 23/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

Springer

Quality:  
High
CiteRatio: 6.0
SJR: 2.135
SNIP: 1.267
open access Open Access

Springer

Quality:  
High
CiteRatio: 6.0
SJR: 1.026
SNIP: 1.34
open access Open Access

Elsevier

Quality:  
High
CiteRatio: 5.9
SJR: 1.175
SNIP: 1.033
open access Open Access
recommended Recommended

Elsevier

Quality:  
High
CiteRatio: 23.9
SJR: 4.491
SNIP: 3.727

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

3.561

11% from 2018

Impact factor for Journal of Viral Hepatitis from 2016 - 2019
Year Value
2019 3.561
2018 4.016
2017 4.237
2016 4.122
graph view Graph view
table view Table view

6.1

2% from 2019

CiteRatio for Journal of Viral Hepatitis from 2016 - 2020
Year Value
2020 6.1
2019 6.0
2018 6.6
2017 8.0
2016 8.0
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has decreased by 11% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 2% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.329

8% from 2019

SJR for Journal of Viral Hepatitis from 2016 - 2020
Year Value
2020 1.329
2019 1.441
2018 1.518
2017 1.683
2016 1.818
graph view Graph view
table view Table view

1.058

2% from 2019

SNIP for Journal of Viral Hepatitis from 2016 - 2020
Year Value
2020 1.058
2019 1.042
2018 0.992
2017 1.152
2016 1.139
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has decreased by 8% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 2% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Journal of Viral Hepatitis

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Wiley

Journal of Viral Hepatitis

The Journal of Viral Hepatitis publishes reviews, original work (full papers) and short, rapid communications in the area of viral hepatitis. It solicits these articles from epidemiologists, clinicians, pathologists, virologists and specialists in transfusion medicine working ...... Read More

Infectious Diseases

Hepatology

Virology

Medicine

i
Last updated on
23 Jun 2020
i
ISSN
1352-0504
i
Impact Factor
High - 1.144
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Yellow faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
apa
i
Citation Type
Numbered
[25]
i
Bibliography Example
Beenakker, C.W.J. (2006) Specular andreev reflection in graphene.Phys. Rev. Lett., 97 (6), 067 007. URL 10.1103/PhysRevLett.97.067007.

Top papers written in this journal

Journal Article DOI: 10.1046/J.1365-2893.2003.00487.X
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
Daniel Lavanchy1

Abstract:

Hepatitis B virus (HBV) infection is a serious global health problem, with 2 billion people infected worldwide, and 350 million suffering from chronic HBV infection. The 10th leading cause of death worldwide, HBV infections result in 500 000 to 1.2 million deaths per year caused by chronic hepatitis, cirrhosis, and hepatocell... Hepatitis B virus (HBV) infection is a serious global health problem, with 2 billion people infected worldwide, and 350 million suffering from chronic HBV infection. The 10th leading cause of death worldwide, HBV infections result in 500 000 to 1.2 million deaths per year caused by chronic hepatitis, cirrhosis, and hepatocellular carcinoma; the last accounts for 320 000 deaths per year. In Western countries, the disease is relatively rare and acquired primarily in adulthood, whereas in Asia and most of Africa, chronic HBV infection is common and usually acquired perinatally or in childhood. More efficacious treatments, mass immunization programs, and safe injection techniques are essential for eliminating HBV infection and reducing global HBV-related morbidity and mortality. Safe and effective vaccines against HBV infection have been available since 1982. The implementation of mass immunization programs, which have been recommended by the World Health Organization since 1991, have dramatically decreased the incidence of HBV infection among infants, children, and adolescents in many countries. However, not all countries have adopted these recommendations and there remains a large number of persons that were infected with HBV prior to the implementation of immunization programs. Antiviral treatment is the only way to reduce morbidity and mortality from chronic HBV infection. Conventional interferon alfa and lamivudine have been the primary treatments to date. Conventional interferon alfa produces a durable response in a moderate proportion of patients but has undesirable side-effects and must be administered subcutaneously three times per week. Lamivudine also produces a response in a modest proportion of patients and causes few side-effects. However, prolonged treatment is often necessary to prevent relapse on cessation of therapy, and continuous treatment can lead to the development of lamivudine resistance. Promising emerging new treatments include adefovir, entecavir and peginterferon alfa-2a (40 kDa). read more read less

Topics:

Hepatitis B virus (60%)60% related to the paper, Hepatitis B (58%)58% related to the paper, Hepatitis B vaccine (54%)54% related to the paper, Lamivudine (53%)53% related to the paper, Disease burden (52%)52% related to the paper
2,552 Citations
Journal Article DOI: 10.1111/J.1365-2893.2005.00651.X
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.
Joanne Micallef1, John M. Kaldor1, Gregory J. Dore1

Abstract:

A large number of studies have reported on spontaneous viral clearance rates in acute hepatitis C infection, however most have been small, and reported rates have varied quite widely To improve the precision of the estimated rate of spontaneous viral clearance, a systematic review was conducted of longitudinal studies Factors... A large number of studies have reported on spontaneous viral clearance rates in acute hepatitis C infection, however most have been small, and reported rates have varied quite widely To improve the precision of the estimated rate of spontaneous viral clearance, a systematic review was conducted of longitudinal studies Factors associated with viral clearance were also examined Inclusion criteria for studies were: longitudinal assessment from time of acute hepatitis C; hepatitis C virus RNA analysis as determinant of viral clearance; untreated for acute hepatitis C Information on study population, and factors that may influence viral clearance were extracted from each study Viral clearance was defined among individuals with at least 6 months follow-up following acute hepatitis C The number of subjects with viral clearance was expressed as a proportion for each study and a weighted mean for proportion was calculated A total of 31 studies were examined Study populations included nine studies of post-transfusion hepatitis, 19 of acute clinical hepatitis, and three of sero-incident cases In total, data was available for 675 subjects and the mean study population was 22 (range 4-67) The proportion with viral clearance ranged from 00 to 08, with a weighted mean of 026 (95% CI 022-029) Factors associated with viral clearance were female gender and acute clinical hepatitis C study population Further studies are required to more clearly define predictors of clearance and guide therapeutic intervention strategies read more read less

Topics:

Viral load (66%)66% related to the paper, Hepatitis (61%)61% related to the paper, Hepatitis C (59%)59% related to the paper, Clearance rate (50%)50% related to the paper
840 Citations
Journal Article DOI: 10.1111/J.1365-2893.2006.00811.X
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases

Abstract:

Summary. Liver stiffness was measured by transient elastography (FibroScan®) in 228 consecutive patients with chronic viral hepatitis, with (115) or without cirrhosis (113), to study its correlations with serum transaminases [alanine aminotransferase (ALT)], fibrosis stage and surrogate noninvasive markers of fibrosis (APRI, ... Summary. Liver stiffness was measured by transient elastography (FibroScan®) in 228 consecutive patients with chronic viral hepatitis, with (115) or without cirrhosis (113), to study its correlations with serum transaminases [alanine aminotransferase (ALT)], fibrosis stage and surrogate noninvasive markers of fibrosis (APRI, FORNS, FibroTest and hyaluronic acid). The dynamic profiles of serum transaminases and liver stiffness were compared by multiple testing in 31 patients during a 6-month follow-up. We identified 8.3 and 14 kPa as the fibrosis ≥F2 and cirrhosis cut-offs, respectively: their sensitivities were 85.2%/78.3%; specificities 90.7%/98.2%; positive predictive values 93.9%/97.8%; negative predictive values 78.8%/81.6%; diagnostic accuracies 87.3%/88.2%. FibroScan® performed better than the other surrogate markers of fibrosis (P < 0.001). Other than fibrosis, other factors independently associated with liver stiffness were ALT for all patients and chronic hepatitis patients (P < 0.001), and 12-month persistently normal ALT (biochemical remission, P < 0.001) in cirrhotics. In patients with biochemical remission either spontaneous or after antiviral therapy (48 of 228, 21%), liver stiffness was lower than in patients with identical fibrosis stage, but elevated ALT (P < 0.001). The liver stiffness dynamic profiles paralleled those of ALT, increasing 1.3- to 3-fold during ALT flares in 10 patients with hepatitis exacerbations. Liver stiffness remained unchanged in 21 with stable biochemical activity (P = 0.001). In conclusion, transient elastography is a new liver parameter that behaves as a reliable surrogate marker of fibrosis in chronic viral hepatitis patients, provided that its relationship with major changes of biochemical activity is taken into account. read more read less

Topics:

Transient elastography (62%)62% related to the paper, FibroTest (60%)60% related to the paper, Liver biopsy (58%)58% related to the paper, Hepatitis (57%)57% related to the paper, Cirrhosis (57%)57% related to the paper
View PDF
649 Citations
Journal Article DOI: 10.1046/J.1365-2893.2003.00450.X
Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Abstract:

Current therapies for chronic hepatitis B (CHB) have a number of limitations, and better treatment options are needed. Peginterferon alpha-2a (40 kDa) is superior to conventional interferon alpha-2a in the treatment of chronic hepatitis C. This is the first report on peginterferon alpha-2a (40 kDa) in the treatment of CHB. In... Current therapies for chronic hepatitis B (CHB) have a number of limitations, and better treatment options are needed. Peginterferon alpha-2a (40 kDa) is superior to conventional interferon alpha-2a in the treatment of chronic hepatitis C. This is the first report on peginterferon alpha-2a (40 kDa) in the treatment of CHB. In this phase II study, 194 patients with CHB not previously treated with conventional interferon-alpha were randomized to receive weekly subcutaneous doses of peginterferon alpha-2a (40 kDa) 90, 180 or 270 microg, or conventional interferon alpha-2a 4.5 MIU three times weekly. Twenty-four weeks of therapy were followed by 24 weeks of treatment-free follow-up. All subjects were assessed for loss of hepatitis B e antigen (HBeAg), presence of hepatitis B antibody (anti-HBe), suppression of hepatitis B virus (HBV) DNA, and normalization of serum alanine transaminase (ALT) after follow-up. At the end of follow-up, HBeAg was cleared in 37, 35 and 29% of patients receiving peginterferon alpha-2a (40 kDa) 90, 180 and 270 microg, respectively, compared with 25% of patients on conventional interferon alpha-2a. The combined response (HBeAg loss, HBV DNA suppression, and ALT normalization) of all peginterferon alpha-2a (40 kDa) doses combined was twice that achieved with conventional interferon alpha-2a (24%vs 12%; P = 0.036). All treatment groups were similar with respect to frequency and severity of adverse events. These results indicate that peginterferon alpha-2a (40 kDa) is superior in efficacy to conventional interferon alpha-2a in chronic hepatitis B based on clearance of HBeAg, suppression of HBV DNA, and normalization of ALT. read more read less

Topics:

HBeAg (65%)65% related to the paper, Hepatitis B (60%)60% related to the paper, Hepatitis B virus (59%)59% related to the paper, Alpha interferon (56%)56% related to the paper, Alanine transaminase (52%)52% related to the paper
476 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Journal of Viral Hepatitis.

It automatically formats your research paper to Wiley formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Journal of Viral Hepatitis format uses apa citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Journal of Viral Hepatitis in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Journal of Viral Hepatitis guidelines and auto format it.

2. Do you follow the Journal of Viral Hepatitis guidelines?

Yes, the template is compliant with the Journal of Viral Hepatitis guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Journal of Viral Hepatitis?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Journal of Viral Hepatitis citation style.

4. Can I use the Journal of Viral Hepatitis templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Journal of Viral Hepatitis.

5. Can I use a manuscript in Journal of Viral Hepatitis that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Journal of Viral Hepatitis that you can download at the end.

6. How long does it usually take you to format my papers in Journal of Viral Hepatitis?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Journal of Viral Hepatitis.

7. Where can I find the template for the Journal of Viral Hepatitis?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Journal of Viral Hepatitis's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Journal of Viral Hepatitis's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Journal of Viral Hepatitis an online tool or is there a desktop version?

SciSpace's Journal of Viral Hepatitis is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Journal of Viral Hepatitis?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Journal of Viral Hepatitis?”

11. What is the output that I would get after using Journal of Viral Hepatitis?

After writing your paper autoformatting in Journal of Viral Hepatitis, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Journal of Viral Hepatitis's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Journal of Viral Hepatitis?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Journal of Viral Hepatitis. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Journal of Viral Hepatitis?

The 5 most common citation types in order of usage for Journal of Viral Hepatitis are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Journal of Viral Hepatitis?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Journal of Viral Hepatitis's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Journal of Viral Hepatitis in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Journal of Viral Hepatitis Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Journal of Viral Hepatitis formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template